Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with p53 gene mutation

International Journal of Cancer

Volumn 95, Issue 4, 2001, Pages 232-239

  Koga, Takaomi ^a   Hashimoto, Shuichi ^a   Sugio, Kenji ^a   Yoshino, Ichiro ^a   Nakagawa, Kazunori ^a   Yonemitsu, Yoshikazu ^a   Sugimachi, Keizo ^a   Sueishi, Katsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Heterogeneity; Immunohistochemistry; Lung adenocarcinoma; MDM2; Micro dissection; p53; PCR SSCP

Indexed keywords

DNA; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; CANCER TISSUE; CHROMOSOME MICRODISSECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; STROMA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENETIC HETEROGENEITY; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035919910     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20010720)95:4<232::AID-IJC1040>3.0.CO;2-5     Document Type: Article

References (40)

1. Pulmonary adenocarcinoma. Classification and molecular biology
2. Surgically curable "early" adenocarcinoma in the periphery of the lung
3. Small adenocarcinoma of the lung
4. Morphogenesis of peripheral type adenocarcinoma of the lung
5. Tumor cell heterogeneity and subpopulations with metastatic ability in differentiated adenocarcinoma of the lung
6. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer
7. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas
8. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma
9. Translation regulation of human p53 gene expression
10. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells
11. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis
12. In vivo ubiquitination and proteasome-mediated degradation
13. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
14. mdm2 expression is induced by wild type p53 activity
15. Transgenic mouse model for studying the transcriptional activity of the p53 protein: Age- and tissue-dependent changes in radiation-induced activation during embryogenesis
16. Involvement of wild-type p53 in pre-B-cell differentiation in vitro
17. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53
18. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
19. The p53-mdm-2 autoregulatory feedback loop
20. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations
21. MDM2 gene amplification and expression in non-small-cell lung cancer: Immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation
22. Tumor extension and cell proliferation in adenocarcinoma of the lung
23. DNA sequence analysis of exon 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies
24. K-ras mutations are a relatively late event in the pathogenesis of the lung carcinogenesis
25. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias
26. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer
27. Localized adenocarcinoma of the lung: Oncogene expression of erbB-2 and p53 in 150 patients
28. Association of p19ARF with mdm2 inhibits ubiquitin ligase activity of mdm2 for tumor suppresser p53
29. Participation of p53 protein in the cellular response to DNA damage
30. Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes?
31. Induction of cellular p53 activity by DNA-damaging agents and growth arrest
32. Small peptides activate the latent sequence-specific DNA binding function of p53
33. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
34. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
35. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
36. Nucleolar Arf sequesters Mdm2 and activates p53
37. Role for p300 in stabilization of p53 in the response to DNA damage
38. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer